If you have been reading about Cyclic AMP and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-23. Numbers and descriptions here follow the published literature rather than marketing material.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
Androgen receptors Calcitriol receptors Corticotropin-releasing hormone receptor 1 Corticotropin releasing hormone receptor 2 Estrogen receptors Follicle-stimulating hormone receptors Glucagon receptors Gonadotropin receptors Gonadotropin-releasing hormone receptors Growth hormone receptors Insulin receptor Luteinizing hormone Progesterone receptors Retinoid receptors Somatostatin receptors Thyroid hormone receptors Thyrotropin receptors
=== Tenure === On August 12, 2022, Stansbury voted to pass the Inflation Reduction Act of 2022. According to a FiveThirtyEight analysis, during the 117th Congress, she voted with President Joe Biden's stated position 100% of the time. When President Donald Trump entered the House chamber for the 2025 Joint Session of Congress, Stansbury held a sign that said "this is not normal" to protest the mass firing of federal workers.
Before entering metamorphosis, the larvae expel a transparent glue from their salivary gland through their mouth, which solidifies within a few seconds and fixes them into a substrate. Then the larvae encapsulate in the puparium and undergo a four-day-long metamorphosis (at 25 °C), after which the adults eclose (emerge).
Sources: en.wikipedia.org
=== 1992–1993: Dirt === In March 1992, the band returned to the studio. With new songs written primarily on the road, the material has an overall darker feel than Facelift, with six of the album's thirteen songs dealing with the subject of addiction. "We did a lot of soul searching on this album. There's a lot of intense feelings." Cantrell said, "We deal with our daily demons through music. All of the poison that builds up during the day we cleanse when we play." On September 29, 1992, Alice in Chains released its second album, Dirt. The album peaked at number six on the Billboard 200 and since its release has been certified 5× platinum by the RIAA, making Dirt the band's highest selling album to date. The album was a critical success, with Huey praising the album as a "major artistic statement, and the closest they ever came to recording a flat-out masterpiece." Chris Gill of Guitar World called Dirt "huge and foreboding, yet eerie and intimate", and "sublimely dark and brutally honest."
After the Colombian government dismantled many of the drug cartels that appeared in the country during the 1980s, left-wing guerrilla groups, and right-wing paramilitary organizations resumed some of their drug trafficking activities. They resorted to extortion and kidnapping for their financing: activities which led to a loss of support from the local population. These funds helped finance paramilitaries and guerrillas, allowing these organizations to buy weapons which were then sometimes used to attack military and civilian targets. Natural resources were found to be correlated with the conflict, while higher per capita income and public investment were associated with reduced conflict intensity. During the presidency of Álvaro Uribe, the government applied more military pressure on the FARC and other outlawed far-left groups. After the offensive, many security indicators improved. As part of a controversial peace process, the AUC (a right-wing paramilitary group) as a formal organization had ceased to function. Colombia achieved a considerable reduction in cocaine production, leading White House drug czar R. Gil Kerlikowske to announce that Colombia was no longer the world's biggest producer of cocaine. In February 2008, millions of Colombians demonstrated against the FARC and other outlawed groups. The Colombian Ministry of Defense reported 19,504 deserters from the FARC between August 2002 and their collective demobilization in 2017, peaking in the year 2008. During these years, the military forces of the Republic of Colombia were strengthened.
=== Senses === As with other varanids, Komodo dragons have only a single ear bone, the stapes, for transferring vibrations from the tympanic membrane to the cochlea. This arrangement means they are likely restricted to sounds in the 400 to 2,000 hertz range, compared to humans who hear between 20 and 20,000 hertz. They were formerly thought to be deaf when a study reported no agitation in wild Komodo dragons in response to whispers, raised voices, or shouts. This was disputed when London Zoo employee Joan Procter trained a captive specimen to come out to feed at the sound of her voice, even when she could not be seen.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.